DT, Université de Montréal, IRICoR and McGill University extend licensing and partnership agreement on G Protein-Coupled Receptor biosensor technology.

Domain Therapeutics will get exclusive access to a new set of more powerful biosensors that will facilitate profiling of more effective and safer drug candidates.

Domain Therapeutics, a France – and Quebec – based biopharmaceutical company that specializes in the research and development of new drug candidates that target G protein-coupled receptors (GPCRs), announces today the signing of a second licensing and partnership agreement on GPCR biosensor technology with Université de Montréal (UdeM) and its commercialization unit, the Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR), as well as with McGill University (McGill). The first licencing agreement was signed at the end of 2013.

Download PDF